Early Analgesia for the Management of Acute Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

PancreasSep 12, 2026 (epub)
Clinical ResearchGastroenterology

Sanjay Bandyopadhyay, Rakesh Khan, Shambo S Samajdar et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of early analgesic interventions, specifically comparing NSAIDs to opioids, in adults with acute pancreatitis (AP). The analysis included 13 randomized controlled trials and found that NSAIDs provided comparable pain relief to opioids while significantly reducing local complications (RR: 0.59, 95% CI: 0.37-0.94).

Key findings

  • NSAIDs provided pain relief comparable to opioids in adults with acute pancreatitis.
  • NSAIDs reduced the incidence of local complications (RR: 0.59, 95% CI: 0.37-0.94).
  • No significant differences were found in the need for rescue analgesia (OR: 0.88, 95% CI: 0.33-2.35).
  • Mortality rates were similar between NSAIDs and opioids (RR: 0.76, 95% CI: 0.19-3.05).

Why it matters

Understanding the comparative efficacy and safety of analgesic options in acute pancreatitis is crucial for optimizing pain management strategies, potentially improving patient outcomes and reducing complications associated with treatment.

What to keep in mind

The findings are limited by study bias and heterogeneity.

Source

PubMed · PMID 42153651

Published in Pancreas. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.